Quantcast
Last updated on April 17, 2014 at 13:47 EDT

Latest Inovio Pharmaceuticals Inc. Stories

2014-01-30 04:21:58

BLUE BELL, Pa., Jan. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview of the company at the 16(th) Annual BIO CEO & Investor Conference in New York, NY. BIO CEO & Investor Conference February 10-11, 2014The Waldorf Astoria New York, NY Inovio PresentationTuesday, February 1110:30 AM ET A live webcast of Dr. Kim's Biotech Showcase presentation can be accessed at...

2014-01-23 04:21:21

Inovio develops DNA-based immune booster (IL-33) that enhances T-cell responses and generates effective CD8 mediated tumor regression BLUE BELL, Pa., Jan. 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the...

2014-01-06 04:21:48

BLUE BELL, Pa., Jan. 6, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present a corporate overview of the company at the Biotech Showcase 2014 investor conference in San Francisco, CA. Biotech Showcase 2014 January 13-15Parc55 HotelSan Francisco, CA Inovio PresentationMonday, January 133:30 PM PT A live webcast of Dr. Kim's Biotech Showcase presentation can be accessed at the following URL:...

2013-12-11 08:30:47

BLUE BELL, Pa., Dec. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, has been invited to participate on an expert panel titled, Ovarian & Cervical Cancer - Evaluating the Role of Immunotherapy Exploring Three Approaches - Dendritic Cells, DNA Plasmids & Liposomal Delivery. Dr. Kim will discuss Inovio's DNA immunotherapy VGX-3100, which was designed to treat cervical pre-cancers and cancers, head...

2013-11-20 04:21:18

No vaccine exists for the MERS virus that has killed 42% of those infected BLUE BELL, Pa., Nov. 20, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon(®) DNA vaccine to prevent and treat this deadly virus. Since 2012, when the virus was first...

2013-11-19 04:23:20

BLUE BELL, Pa., Nov. 19, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported that the International Vaccine Institute (IVI) appointed Inovio's President and CEO, Dr. J. Joseph Kim, to the IVI Board of Trustees where he will serve a three-year term to oversee the governance and management of the institute. Internationally recognized vaccine experts Professor Fred Binka and Dr. George R. Siber were also named to the board today. The International Vaccine Institute...

2013-11-18 04:22:26

BLUE BELL, Pa., Nov. 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will be attending Brean Capital's 2013 Life Sciences Summit in New York, and will present at the 25(th) Annual Piper Jaffray Healthcare Conference in New York and LD Micro's 6(th) Annual Main Event in Los Angeles. Brean Capital 2013 Life Sciences Summit November 25, 2013ConveneNew York, NY 25th Annual Piper Jaffray Healthcare...

2013-11-14 00:22:52

Korean American Pharma Society Recognizes CEO's Pioneering Efforts In Developing DNA Vaccines BLUE BELL, Pa., Nov. 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its President & CEO, Dr. J. Joseph Kim, has been selected to receive the 2013 Achievement in Drug Discovery and Development Award from the Korean American Society in Biotech and Pharmaceuticals ("KASBP"). The Society aims to contribute to the growth of drug discovery and...

2013-11-12 08:33:56

Inovio marks quarter with significant partnership with Roche BLUE BELL, Pa., Nov. 12, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended September 30, 2013. Total revenue was $9.5 million and $11.7 million for the three and nine months ended September 30, 2013, compared to $855,000 and $3.0 million for the same periods in 2012. Total operating expenses were $8.7 million and $23.3 million for the three and nine...

2013-11-04 04:22:03

BLUE BELL, Pa., Nov. 4, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on Tuesday, November 12, 2013, at 8:30 a.m. ET. Management will provide an update on the company, discuss third quarter results, and discuss expectations for the future. The audio presentation will be broadcast online at...